MUC1

GeoVax Announces Issuance of Cancer Vaccine Patent

Retrieved on: 
Tuesday, March 22, 2022
Company, MUC1, Cancer, Zika virus, Colon, Malaria, Human, Vaccination, Lung, Patent, Ovary, GeoVax, Form, Risk, Immunotherapy, University of North Carolina at Greensboro, Form S-3, IND, Vaccine, Neoplasm, Breast, Biotechnology, SEC, Prostate, Head, Research, Antigen, Cyclin B1, CEO, Food, Â, Immunodeficiency, Virus-like particle, Safety, HNSCC, Tumor-associated macrophage, Nasdaq, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Infection, Method, FDA, MVA, Form 10-Q, University, Patient, Pharmaceutical industry

Atlanta, GA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11278607 to GeoVax, pursuant to the Company’s patent application No. 16/068,527 entitled “Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen.”

Key Points: 
  • Atlanta, GA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No.
  • 11278607 to GeoVax, pursuant to the Companys patent application No.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms.
  • The Companys portfolio of wholly owned, co-owned, and in-licensed intellectual property stands at over 70 granted or pending patent applications spread over 20 patent families.

Minerva Biotechnologies Announces Opening 1st-In-Human Phase I/II Trial of a MUC1* Targeting CAR T for Metastatic Breast Cancers at City of Hope

Retrieved on: 
Tuesday, February 1, 2022
Biotechnology, Practice Management, FDA, Managed Care, Health, Pharmaceutical, Oncology, Research, Hospitals, Science, Clinical Trials, Growth, CEO, Safety, City, Patient, CAR, City of Hope, Cell, MUC1, Physician, Minerva, Tumor microenvironment, Breast, Therapy, HyperStealth Biotechnology Corporation, Antibody, Control, Vaccine

Minerva Biotechnologies Corporation announced today that its trial of huMNC2-CAR44 T cells (NCT04020575) has now opened at City of Hope, Duarte, California.

Key Points: 
  • Minerva Biotechnologies Corporation announced today that its trial of huMNC2-CAR44 T cells (NCT04020575) has now opened at City of Hope, Duarte, California.
  • This is a first-in-human trial targeting the tumor-associated form of MUC1, called MUC1* (muk 1 star).
  • MUC1* is the transmembrane cleavage product that is a growth factor receptor that drives growth of an estimated 93% of breast cancers.
  • NCT04020575 is a first-in-human trial of huMNC2-CAR44, an autologous CAR T therapy targeting MUC1* in metastatic breast cancer in patients with MUC1* reactive tumors.

GeoVax Issues Shareholder Update Letter

Retrieved on: 
Tuesday, January 4, 2022
Immunodeficiency, Virus-like particle, Vaccine, Coronavirus, City of Hope, ICI, RNA transfection, Refrigeration, Food, Program, City, Immunity, Patient, Capsid, Cancer, Goal, Membrane protein, Science, COVID-19, MUC1, Protein, Conference, Pfizer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Immunotherapy, Population, Technology, United States Department of Defense, GeoVax, Nasdaq, Beta, ICIS, Animal, Pharmaceutical industry, Omicron

ATLANTA, GA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today issued an update letter from Chairman and CEO, David Dodd, to the Company’s shareholders and other interested parties. The letter is posted to the Company’s website and is appended in its entirety to the end of this press release.

Key Points: 
  • Thank you for your continued support of GeoVax and sharing in our efforts to advance the application of our expertise, science, and technology towards improving the lives of millions worldwide.
  • In this trial, we are conducting a direct comparison of GEO-CM04S1 to the Pfizer/BioNTech mRNA vaccine.
  • We also believe that the current vaccines, based on mRNA and adenovirus vaccine platforms, may be less effective and protective within immunocompromised populations.
  • In simple terms, we believe our vaccine has a better chance of addressing the issues and dangers of evolving variants of concern, which we expect will continue to emerge.

Merck Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus

Retrieved on: 
Monday, November 22, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Interferon beta-1a, PARP, Health care, Electronics, Central nervous system, Mall of America, Lupus, Neck, TLR, Infection, Neurology, Development, MUC1, CNS, Ovarian cancer, Head, Neoplasm, MS, Health, Cancer, Chemoradiotherapy, SCLC, Merck Millipore, Gene editing, ADC, Trial of the century, Squamous cell carcinoma, Large-cell lung carcinoma, IAP, Phase II, BTK, Phase, SCCHN, CLE, DDR, Control, Standard of care, Intelligence, Patient, Safety, MET, ATR, Multiple sclerosis, EGFR, TLR8, Merck Serono, Entrepreneurship, OS, Science, RMS, SLE, Fine chemical, Pharmaceutical industry, Medical device, Vaccine

Ongoing Phase III TrilynX study for previously untreated unresectable locally advanced (LA) SCCHN in combination with platinum-based chemoradiotherapy.

Key Points: 
  • Ongoing Phase III TrilynX study for previously untreated unresectable locally advanced (LA) SCCHN in combination with platinum-based chemoradiotherapy.
  • Highly specific potential first-in-class immune modulator blocking the activation of Toll-like receptor (TLR)7 and TLR8, known to be activated in lupus.
  • Initiation of Phase II studies in systemic lupus erythematosus (SLE) / cutaneous lupus erythematosus (CLE) in the first half of 2022.
  • All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website.

Merck KGaA, Darmstadt, Germany Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus

Retrieved on: 
Wednesday, March 23, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Interferon beta-1a, PARP, Health care, Electronics, Central nervous system, Mall of America, Lupus, Neck, TLR, Infection, Neurology, Development, MUC1, CNS, Ovarian cancer, Head, Neoplasm, MS, Health, Cancer, Chemoradiotherapy, SCLC, Merck Millipore, Gene editing, Merck Group, ADC, Trial of the century, Squamous cell carcinoma, Large-cell lung carcinoma, IAP, Phase II, BTK, Phase, SCCHN, CLE, DDR, Control, Standard of care, Intelligence, Patient, Safety, MET, Merck, ATR, Multiple sclerosis, EGFR, TLR8, Merck Serono, Entrepreneurship, OS, Science, RMS, SLE, Fine chemical, Pharmaceutical industry, Medical device, Vaccine, Biotechnology, Pharmaceutical, Health, Oncology

Ongoing Phase III TrilynX study for previously untreated unresectable locally advanced (LA) SCCHN in combination with platinum-based chemoradiotherapy.

Key Points: 
  • Ongoing Phase III TrilynX study for previously untreated unresectable locally advanced (LA) SCCHN in combination with platinum-based chemoradiotherapy.
  • Initiation of Phase II studies in systemic lupus erythematosus (SLE) / cutaneous lupus erythematosus (CLE) in the first half of 2022.
  • Merck KGaA, Darmstadt, Germany has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS).
  • Merck KGaA, Darmstadt, Germany aims to improve the lives of patients by addressing areas of unmet medical needs.

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent

Retrieved on: 
Tuesday, November 16, 2021
Virus-like particle, Cancer, Breast, Immunodeficiency, National, Food, COVID-19, Immunotherapy, Acquisition, Infection, Lung, Colon, NIH, Safety, Technology, Method, GeoVax, Â, Biotechnology, GLOBE, Program, Patent, MVA, Patient, HIV Vaccine Trials Network, FDA, CAR, HNSCC, RNA transfection, Neoplasm, Ovary, CEO, MUC1, Zika virus, COVID-19 vaccine, Human, Protein, HVTN, Vaccine, City, SEC, Form S-3, Head, Form, Prostate, Antigen, Immune system, HIV, City of Hope, Pfizer, Tumor-associated macrophage, Risk, Food and Drug Administration, Company, VLP, Pfizer–BioNTech COVID-19 vaccine, Nasdaq, Form 10-Q, Cyclin B1, Intellectual property, Pharmaceutical industry

Atlanta, GA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 16/068,527 entitled “Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen.” In general, the claims to be granted in the patent cover GeoVax’s vector platform for expressing tumor associated antigens in virus-like particles (VLPs) from a Modified Vaccinia Ankara (MVA) viral vector and encompass GeoVax’s Mucin 1 (MUC1) tumor-associated antigen immunotherapy candidate.

Key Points: 
  • Atlanta, GA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No.
  • David Dodd, GeoVax President and CEO, commented, This patent allowance adds to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using novel patented platforms.
  • GeoVaxs Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform utilizes MVA, a large virus capable of carrying several vaccine antigens, that expresses proteins that assemble into VLP immunogens in the person receiving the vaccine.

OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, September 1, 2021
SingHealth, Oregovomab, Terminology, Ovarian cancer, Drug combination, Korea University College of Science, PD-1, KOREA, Paclitaxel, Korean Government Scholarship Program, Cancer, Carboplatin, Korea University College of Medicine, Doxorubicin, Survival, HER2/neu, Bevacizumab, MUC1, PSA, Disease, Platinum, Gynecologic Oncology (journal), Death, TSX Venture Exchange, Antibody, Clinical trial, Overalls, Safety, Risk, Cancer immunology, Patient, Immunoglobulin G, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Toxicity, Immunization, Hospital, Nivolumab, Pharmaceutical industry

The study will establish the safety and compatibility of the combination of these agents as possible approaches in patient management(ClinicalTrials.gov Identifier: NCT04938583).

Key Points: 
  • The study will establish the safety and compatibility of the combination of these agents as possible approaches in patient management(ClinicalTrials.gov Identifier: NCT04938583).
  • The second study(ORION-02), led by Clinical Assistant Professor Jack Chan, is being conducted at a single centre in Singapore (National Cancer Centre Singapore).
  • OncoQuest has completed a Phase II study using oregovomab in combination with a TLR-3 agonist (Hiltonol) in the recurrent ovarian cancer setting (ClinicalTrials.gov Identifier: NCT03162562).
  • OncoQuest is also in the process of initiating a clinical trial using oregovomab with niraparib in the recurrent ovarian cancer setting.

PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 12, 2021
Transfer, SEC, Population, Merck & Co., Radiation, Clinical trial, MD Anderson Cancer Center, Company, Research, Merck, Communication, Risk, Forward-looking statement, R, COVID-19, Biotechnology, Annual general meeting, PDS, Goal, Food, Sale, Lung, Partnership, Immune system, Technology, Colon, Russell, Prostate, Nasdaq, Immunotherapy, Survival, Net, Society, National Cancer Institute, GLOBE, University, NCI, MUC1, HPV16, Growth, International, American Society of Clinical Oncology, Food and Drug Administration, Cervical cancer, Twitter, ASCO, New Jersey Economic Development Authority, Infection, PDSB, Cancer, Nature, Coronavirus Scientific Advisory Board (Turkey), Breast, Review, Patient, National, Pharmaceutical industry, Vaccine, Animal

FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, will discuss its financial results for the quarter ended June 30, 2021 and provide a business update on its conference call today.

Key Points: 
  • FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, will discuss its financial results for the quarter ended June 30, 2021 and provide a business update on its conference call today.
  • Added to Russell Microcap Index as part of the 2021 annual reconstitution based on market-capitalization rankings and style attributes.
  • The second quarter has been quite significant for PDS Biotech in providing the first demonstration of the clinical potential of the Versamune-based products in treating advanced, treatment-resistant cancers.
  • PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform.

PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences

Retrieved on: 
Wednesday, July 28, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Branches of biology, Virotherapy, Immunotherapy, MUC1, Checkpoint inhibitor

In the second group, patients who in addition had failed treatment with checkpoint inhibitors, tumor reduction was seen in 58% (7 of 12) patients.

Key Points: 
  • In the second group, patients who in addition had failed treatment with checkpoint inhibitors, tumor reduction was seen in 58% (7 of 12) patients.
  • The upcoming investor conferences will offer leadership the opportunity to provide an update on both ongoing PDS0101 Phase 2 clinical trials, as well as preparations to move two other investigational compounds PDS0102 (Versamune-TARP) and PDS0103 (Versamune-MUC1) into human testing.
  • PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform.
  • PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers.

Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Biotechnology, MUC1, Monoclonal antibody, Gatipotuzumab, Antibody-drug conjugate

In this study, 50 patients with refractory solid tumors were treated with both antibodies in 5 centers in Germany, Italy and Spain.

Key Points: 
  • In this study, 50 patients with refractory solid tumors were treated with both antibodies in 5 centers in Germany, Italy and Spain.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 150 GlycoTargets with antibodies against several of these targets currently under development.
  • Currently six clinical and pre-clinical programs based on the TA-MUC1 GlycoTarget are under development by Glycotope or its licensing partners.